Pure Red Cell Aplasia Induced by Epoetin Zeta

Overview

Journal Clin Kidney J

Publisher Oxford University Press

Specialty Nephrology

Date 2016 Aug 2

PMID 27478604

Citations 3

Authors

Vincenzo Panichi

Guido Ricchiuti

Alessia Scatena

Lucia Del Vecchio

Francesco Locatelli

Affiliations

Soon will be listed here.

Abstract

Pure red cell aplasia (PRCA) may develop in patients with chronic kidney disease receiving erythropoiesis-stimulating agents (ESA). We report on a 72-year-old patient who developed hypo-proliferative anaemia unresponsive to ESA following the administration of epoetin zeta subcutaneously for 7 months. On the basis of severe isolated hypoplasia of the erythroid line in the bone marrow and high-titre neutralizing anti-erythropoietin antibodies (Ab), a diagnosis of Ab-mediated PRCA was made. Epoetin zeta was discontinued and the patient was given steroids. This was associated with anaemia recovery. To our knowledge this is the first PRCA case related to epoetin zeta.

Citing Articles

A Case of Erythropoietin (EPO)-Induced Pure Red Cell Aplasia and Its Treatment Efficacy With Desidustat.

Kashiv P, Malde S, Dubey S, Gupta S, Pawar T, Sejpal K Cureus. 2024; 16(6):e62022.

PMID: 38989377 PMC: 11235398. DOI: 10.7759/cureus.62022.

Pure red cell aplasia and anti-erythropoietin antibodies in patients on hemodialysis: a report of two cases and a literature review.

Lacreta G, Bucharles S, Sevignani G, Riella M, do Nascimento M J Bras Nefrol. 2018; 41(1):145-151.

PMID: 30160771 PMC: 6534017. DOI: 10.1590/2175-8239-jbn-2018-0054.

Aapro M, Krendyukov A, Schiestl M, Gascon P BioDrugs. 2018; 32(2):129-135.

PMID: 29417431 PMC: 5878200. DOI: 10.1007/s40259-018-0262-9.

References

Seidl A, Hainzl O, Richter M, Fischer R, Bohm S, Deutel B . Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res. 2011; 29(6):1454-67. PMC: 3349029. DOI: 10.1007/s11095-011-0621-4. View

Bennett C, Cournoyer D, Carson K, Rossert J, Luminari S, Evens A . Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005; 106(10):3343-7. PMC: 1895064. DOI: 10.1182/blood-2005-02-0508. View

Herrington W, Wieser C, Rosenkranz A . Pure red cell aplasia after treatment of renal anaemia with epoetin theta. Clin Kidney J. 2015; 6(5):539-42. PMC: 4438400. DOI: 10.1093/ckj/sft085. View

Dellanna F, Fluck R, Lonnemann G, Wild C, Iwanowitsch A, Meissner R . Results from a safety cohort of patients with renal anemia receiving the biosimilar epoetinzeta: The PASCO I study. Clin Nephrol. 2015; 84(5):280-8. DOI: 10.5414/CN108484. View

Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian J, Martin-Dupont P . Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002; 346(7):469-75. DOI: 10.1056/NEJMoa011931. View

Zerbi S, Cozzi G, Mercieri A, Faranna P, Ruggiero P, Pedrini L . Successful corticosteroid therapy for epoetin-beta-induced pure red-cell aplasia in a hemodialysis patient. Am J Hematol. 2006; 81(10):803-4. DOI: 10.1002/ajh.20587. View

Macdougall I, Roger S, de Francisco A, Goldsmith D, Schellekens H, Ebbers H . Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int. 2012; 81(8):727-32. DOI: 10.1038/ki.2011.500. View

Gershon S, Luksenburg H, Cote T, Braun M . Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med. 2002; 346(20):1584-6; author reply 1584-6. DOI: 10.1056/NEJM200205163462015. View

Kwong Y, Wong K, Liang R, Chu Y, Chan L, Chan T . Pure red cell aplasia: clinical features and treatment results in 16 cases. Ann Hematol. 1996; 72(3):137-40. DOI: 10.1007/s002770050151. View

10.

Macdougall I, Casadevall N, Locatelli F, Combe C, London G, Di Paolo S . Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol Dial Transplant. 2014; 30(3):451-60. PMC: 4339685. DOI: 10.1093/ndt/gfu297. View

11.

Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt K, Macdougall I . Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet. 2004; 363(9423):1768-71. DOI: 10.1016/S0140-6736(04)16302-2. View

12.

Haag-Weber M, Eckardt K, Horl W, Roger S, Vetter A, Roth K . Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol. 2011; 77(1):8-17. DOI: 10.5414/cn107304. View

13.

Hermeling S, Schellekens H, Crommelin D, Jiskoot W . Micelle-associated protein in epoetin formulations: aA risk factor for immunogenicity?. Pharm Res. 2004; 20(12):1903-7. DOI: 10.1023/b:pham.0000008034.61317.02. View

14.

Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf-Pflugmann M . Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther. 2010; 27(2):105-17. DOI: 10.1007/s12325-010-0012-y. View